Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer.

A positive trend in OS was also observed with the use of atezolizumab in stage II–IIIA with positive PD-L1 expression, likely driven by the benefit witnessed in those with the PD-L1 ≥ 50% [ 47 ].

also in 11,005 other papers